Description
Gliclada Tablets with Prolonged Release 60 mg. №30
Ingredients:
Each tablet contains 60 mg of Gliclazide.
Mechanism of Action:
Gliclazide, the active ingredient in Gliclada tablets, is a sulfonylurea derivative that acts by stimulating insulin release from pancreatic beta cells. It enhances peripheral glucose utilization and reduces hepatic glucose production, thereby lowering blood sugar levels.
Pharmacological Properties:
Gliclada tablets exhibit hypoglycemic effects by promoting insulin secretion and improving insulin sensitivity. The prolonged-release formulation ensures sustained drug levels in the blood, contributing to better glycemic control.
Indications for Use:
Gliclada tablets are indicated for the treatment of type 2 diabetes mellitus. They are prescribed to help regulate blood glucose levels and mitigate the risk of diabetic complications.
Contraindications:
Avoid using Gliclada tablets in individuals with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, or a history of hypersensitivity to sulfonylureas. Caution is advised in patients with a sulfa allergy.
Side Effects:
Common side effects of Gliclada tablets may include hypoglycemia, gastrointestinal disturbances, skin reactions, and hematological abnormalities. Regular monitoring and dose adjustments are essential to manage these adverse effects.
Usage Instructions:
The recommended dosage of Gliclada tablets is one tablet daily, preferably taken with breakfast. Swallow the tablet whole with a glass of water; do not crush or chew it. Adhere to the dosing regimen prescribed by your healthcare provider for optimal therapeutic outcomes.
Benefits Compared to Analogues:
Gliclada tablets with prolonged release offer the advantage of once-daily dosing, ensuring convenience and improved medication adherence compared to conventional formulations. The sustained drug release profile minimizes the risk of fluctuations in blood glucose levels, providing more stable glycemic control.
Suitable Patient Groups:
Gliclada tablets are suitable for adult patients with type 2 diabetes mellitus. They can be used in elderly individuals; however, dose adjustments may be necessary based on renal function. The safety and efficacy of Gliclada in pediatric populations have not been established.
Storage Conditions and Shelf Life:
- Store Gliclada tablets in a cool, dry place away from direct sunlight.
- Keep the medication out of reach of children and pets to prevent accidental ingestion.
Packaging Description:
Gliclada tablets are supplied in a blister pack containing 30 tablets. The packaging is designed to maintain the stability and integrity of the tablets, protecting them from environmental factors.
Clinical Evidence and Proven Effectiveness:
Gliclada tablets with prolonged release 60 mg have demonstrated efficacy in reducing blood glucose levels in patients with type 2 diabetes. Clinical studies have shown that Gliclada effectively stimulates insulin secretion and enhances insulin sensitivity, leading to improved glycemic control. The safety and tolerability profile of Gliclada has been established, making it a valuable therapeutic option for diabetes management.
